ReShape Lifesciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	8.68	11.24	13.6	11.3	3.28	9.1	9.91	3.39	4.04	3.54
Revenue Growth (YoY)	-22.79%	-17.35%	20.36%	244.38%	-63.95%	-8.20%	192.19%	-15.99%	14.13%	-
Cost of Revenue	3.13	4.44	5.25	5.04	2.95	5.42	4.83	2.81	2.5	2.91
Gross Profit	5.55	6.8	8.35	6.26	0.33	3.68	5.09	0.58	1.54	0.63
Selling, General & Admin	17.87	31.34	33.21	15.22	16.67	29.95	28.83	10.22	3.49	4.7
Research & Development	2.32	2.54	2.37	3.5	6.89	10.7	10.65	9.87	12.98	5.77
Other Operating Expenses	0.74	19.27	30.65	0	0.06	0	0	0	0.04	0
Operating Expenses	20.93	53.15	66.23	18.72	23.62	40.64	39.48	20.09	16.51	10.47
Operating Income	-15.38	-46.35	-57.88	-12.46	-23.29	-36.97	-34.39	-19.51	-14.97	-9.84
Interest Expense / Income	-0.03	0.11	0.83	2.05	0.39	0.23	0.14	0.48	0.55	0.22
Other Expense / Income	-4.02	0.13	4.71	7.31	-	0.18	0.24	0.49	0.03	-0.18
Pretax Income	-11.34	-46.59	-63.42	-21.81	-23.68	-37.38	-34.77	-20.47	-15.55	-9.88
Income Tax	0.05	-0.38	-0.27	-0.18	0	0	0	0	0	0
Net Income	-11.39	-46.21	-63.15	-21.63	-23.68	-37.38	-34.77	-20.47	-15.55	-9.88
Shares Outstanding (Basic)	6	0	0	0	0	0	0	0	0	0
Shares Outstanding (Diluted)	6	0	0	0	0	0	0	0	0	0
Shares Change	1303.56%	94.21%	179.82%	148.88%	147.23%	13.88%	295.91%	636.91%	7.91%	-
EPS (Basic)	-1.91	-108.90	-288.97	-277.00	-754.50	-2946.00	-3120.00	-7270.51	-40710.04	-27915.03
EPS (Diluted)	-1.91	-108.90	-288.97	-277.00	-754.50	-2946.00	-3120.00	-7270.51	-40710.04	-27915.03
Free Cash Flow	-16.97	-21.99	-15.73	-8.94	-23.06	-30.71	-31.67	-19.72	-11.53	-10.18
Free Cash Flow Per Share	-2.85	-51.83	-71.97	-114.48	-734.90	-2420.04	-2841.29	-7004.11	-30160.68	-28719.74
Gross Margin	63.93%	60.52%	61.38%	55.42%	10.09%	40.41%	51.29%	17.21%	38.03%	17.72%
Operating Margin	-177.26%	-412.38%	-425.60%	-110.25%	-709.88%	-406.16%	-346.89%	-574.86%	-370.74%	-278.04%
Profit Margin	-131.22%	-411.16%	-464.31%	-191.43%	-721.61%	-410.67%	-350.71%	-603.24%	-385.05%	-279.20%
Free Cash Flow Margin	-195.55%	-195.68%	-115.64%	-79.12%	-702.83%	-337.48%	-319.42%	-581.20%	-285.34%	-287.51%
EBITDA	-11.21	-44.33	-60.62	-18.1	-22.4	-36.57	-34.3	-19.8	-14.84	-9.5
EBITDA Margin	-129.14%	-394.38%	-445.71%	-160.15%	-682.63%	-401.80%	-346.02%	-583.52%	-367.32%	-268.30%
Depreciation & Amortization	0.15	2.15	1.97	1.67	0.89	0.58	0.33	0.19	0.17	0.17
EBIT	-11.36	-46.48	-62.59	-19.76	-23.29	-37.15	-34.63	-19.99	-15	-9.66
EBIT Margin	-130.92%	-413.53%	-460.21%	-174.90%	-709.88%	-408.19%	-349.34%	-589.18%	-371.45%	-272.99%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).